Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials

(2016) Tobias Derfuss et al.   Multiple Sclerosis and Related Disorders

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

(2014) Vincent van Pesch et al.   ACTA NEUROLOGICA BELGICA

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

(2013) Michael Hutchinson et al.   JOURNAL OF NEUROLOGY

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study

(2013) Amit Bar-Or et al.   JOURNAL OF NEUROLOGY

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

(2012) Aaron E Miller et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

(2011) Ludwig Kappos et al.   Multiple Sclerosis Journal

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY